The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.p

Tumor lysis syndrome (TLS)

Publications

Kenealy MK, Prince HM, Hönemann D

Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.

Pharmacotherapy 2006 Aug;26;1205-6; discussion 1206 — 2006 Aug — 1205-6; discussion 1206

Jaskiewicz AD, Herrington JD, Wong L

Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.

Pharmacotherapy 2005 Dec;25;1820-5 — 2005 Dec — 1820-5

Terpos E, Politou M, Rahemtulla A

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.

Journal of cancer research and clinical oncology 2004 Oct;130;623-5 — 2004 Oct — 623-5